Key Points
- CEO Travis Dalton bought 5,110 Claritev shares at an average price of $29.34, spending about $149,927. The purchase increased his stake by 9.77% to 57,432 shares.
- Claritev reported quarterly EPS of $1.77, beating analysts’ consensus estimate of a $3.68 loss; revenue was $268.31 million.
- Analysts’ consensus rating is “Moderate Buy”, with an average price target of $44.83.
Claritev (NYSE:CTEV - Get Free Report) CEO Travis Dalton bought 5,110 shares of Claritev stock in a transaction dated Wednesday, November 11th. The stock was acquired at an average cost of $29.34 per share, with a total value of $149,927.40. Following the transaction, the chief executive officer owned 57,432 shares of the company's stock, valued at $1,685,054.88. This trade represents a 9.77% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Travis Dalton also recently made the following trade(s):
- On Thursday, August 27th, Travis Dalton purchased 4,500 shares of Claritev stock. The stock was acquired at an average price of $38.81 per share, for a total transaction of $174,645.00.
- On Friday, August 28th, Travis Dalton purchased 1,950 shares of Claritev stock. The shares were acquired at an average cost of $38.48 per share, for a total transaction of $75,036.00.
Claritev Price Performance
Claritev stock traded down $0.01 during midday trading on Friday, hitting $26.89. The company's stock had a trading volume of 175,323 shares, compared to its average volume of 312,186. Claritev has a 1-year low of $11.50 and a 1-year high of $55.50. The company has a 50-day moving average price of $26.18 and a two-hundred day moving average price of $25.46. The company has a market cap of $455.79 million, a price-to-earnings ratio of -1.64 and a beta of 1.05.
Claritev (NYSE:CTEV - Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported $1.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.68) by $5.45. The business had revenue of $268.31 million during the quarter. Sell-side analysts forecast that Claritev will post -15.02 EPS for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on CTEV shares. Piper Sandler reiterated an "overweight" rating and issued a $73.00 price target on shares of Claritev in a research report on Wednesday, August 12th. Canaccord Genuity Group increased their price target on Claritev from $37.00 to $43.00 and gave the stock a "buy" rating in a research report on Monday, August 10th. Weiss Ratings reissued a "sell (d-)" rating on shares of Claritev in a research report on Monday, September 21st. Wells Fargo & Company raised their price objective on Claritev from $22.00 to $30.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 12th. Finally, Zacks Research raised Claritev from a "strong sell" rating to a "hold" rating in a report on Thursday, August 13th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $44.83.
Get Our Latest Research Report on Claritev
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Public Investment Fund acquired a new stake in Claritev during the second quarter worth about $43,703,438. Marshall Wace LLP increased its holdings in Claritev by 1,569.2% in the 3rd quarter. Marshall Wace LLP now owns 225,890 shares of the company's stock valued at $4,782,000 after buying an additional 212,357 shares during the period. RBF Capital LLC increased its holdings in Claritev by 0.8% in the 1st quarter. RBF Capital LLC now owns 135,314 shares of the company's stock valued at $2,211,000 after buying an additional 1,127 shares during the period. Bank of America Corp DE raised its position in shares of Claritev by 146.6% in the 1st quarter. Bank of America Corp DE now owns 97,795 shares of the company's stock valued at $1,598,000 after buying an additional 58,133 shares in the last quarter. Finally, FAS Wealth Partners Inc. raised its position in shares of Claritev by 49.5% in the 1st quarter. FAS Wealth Partners Inc. now owns 46,477 shares of the company's stock valued at $759,000 after buying an additional 15,380 shares in the last quarter. Institutional investors and hedge funds own 87.15% of the company's stock.
Claritev Company Profile
(
Get Free Report)
Claritev, formerly known as MultiPlan, provides technology-enabled services intended to help manage healthcare costs and support payment accuracy. Its offerings include access to provider networks, claims and payment solutions, and data analytics for evaluating healthcare costs and utilization. The company serves health plans, self-insured employers, third-party administrators and other participants in the U.S. healthcare system. Its services are designed to help customers identify cost-management opportunities and support more efficient healthcare transactions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
